Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
May 25, 2023 16:26 ET | Adamis Pharmaceuticals Corporation
DMK CEO, Ebrahim (Eboo) Versi, MD, PhD, named CEO and Chairman of the combined companyCombined company will have commercial products and a library of development candidates, including two clinical...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023 16:47 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company focused on developing and commercializing products in...
Insights on the Naloxone Global Market to 2030 - Increasing Prevalence of Opioid Overdoses Remains as The Most Impactful Driver
January 30, 2023 09:33 ET | Research and Markets
Dublin, Jan. 30, 2023 (GLOBE NEWSWIRE) -- The "Naloxone Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to...
Heart to Heart CPR Raises Awareness of Ontario's NEW Workplace Naloxone Requirements Effective June 1, 2023
January 10, 2023 08:08 ET | Heart to Heart First Aid CPR Services Inc
TORONTO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- As of June 1, 2023, the Occupational Health and Safety Act (OHSA) will require workplaces to have a naloxone kit if an employer becomes aware, or ought...
Stop Opioid Overdoes Naloxone
Fentanyl Drives Fatal Overdoses to Over 107,000 Annually in the U.S. - Healthcare Providers' Effort to Fight Back
August 24, 2022 09:00 ET | Cordant Health Solutions
PORTLAND, Ore., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Cordant Health Solutions®, a leader in providing innovative tools for addiction treatment programs, is partnering with addiction treatment providers...
ZIMHI Device.png
US WorldMeds Launches
July 05, 2022 11:32 ET | US WorldMeds
LOUISVILLE, Ky., July 05, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds) announces ZIMHI™ (naloxone HCL Injection) 5mg/0.5mL is now available for ordering by public interest groups through the...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
June 01, 2022 08:00 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Global Suboxone Market
Global Global Suboxone Market Analysis/Forecast Report 2022-2030: Increasing Product Launches is Expected to Drive Growth
May 24, 2022 06:49 ET | Research and Markets
Dublin, May 24, 2022 (GLOBE NEWSWIRE) -- The "Global Suboxone Market by Type, Formulation, Distribution Channel, and Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
December 01, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of...
Adamis Pharmaceuticals logo
Adamis Receives FDA Approval for ZIMHI
October 18, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone...